Inspire Medical Systems, Inc.
INSP · Price history
Price at last available close
$71.30
+$1.30 (+1.86%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Inspire Medical Systems, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U. S. and international markets.
How they make money
Inspire Medical Systems generates revenue by selling its proprietary neurostimulation system to hospitals and ambulatory surgery centers. The company utilizes a direct sales organization in the U.S. and Europe, while employing third-party distributors in Japan and Singapore to facilitate the adoption of its therapy for obstructive sleep apnea.
Products & services
The Inspire system is an FDA-approved, implantable neurostimulation technology designed to treat moderate to severe obstructive sleep apnea by providing a mask-free and hose-free alternative to traditional therapies.
Brands & revenue mix
The primary brand for the company's proprietary neurostimulation therapy system.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Customer concentration
The company does not disclose specific customer concentration figures, noting that it sells to a broad network of hospitals and ambulatory surgery centers.
Suppliers, materials & equipment
- Contract Manufacturers — The company relies on third-party manufacturers for the production of its implantable devices and components; specific supplier names are not disclosed.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
64
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
69
Fair
Financial Strength
65
Business Quality / Moat
80
Management
94
Growth Quality
33
Risk / Durability
55
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
61
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
57/100
Building Historical Record
Model Score 57/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Valuation scores attractively
- •Recent buyback activity is present
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for INSP
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving INSP's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is INSP's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is INSP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is INSP's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
64
Opportunity Score
61
Market Cap
$2.06B
P/E Ratio
14.9
EPS
$4.66
52-Week High
$147.03
52-Week Low
$38.91
Beta
0.70
Intrinsic Value
$179.44
Analyst Target
$60.00
Shares Outstanding
29.8M
Total Revenue
$898.7M
Total Debt
$29.1M
Dividend
No current dividend
Liquidation Value / Share
$27.74
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for INSP
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on INSP.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary FDA-approved neurostimulation technology.
- +Direct sales organization in key markets.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Dependence on third-party manufacturers.
- −Regulatory approval and compliance requirements.
- −Reimbursement coverage by insurance providers.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
68
Aug 14, 2026
Change
-4.1
points
Current Score
64
Oct 1, 2026
Category Changes
INSP decreased 4.1 points because Revenue declined by 2.1 points, Asset declined by 2.7 points, Capital declined by 15 points.
Positive Contributors
- + Valuation improved by 14.6 points
Negative Contributors
- − Revenue declined by 2.1 points
- − Asset declined by 2.7 points
- − Capital declined by 15 points
Projected Score
Projected Score
59
Projected Change
-4.8 points
Preliminary comparable-period financial changes suggest decline of approximately 4.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$71.30
Model Intrinsic Value
$179.44
Difference
−$108.14
-60.3% vs IV
Margin of Safety
60.3%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $898.7M | $912.0M | $802.8M | $624.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $124.6M | $133.2M | $123.0M | $96.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $774.1M | $778.8M | $679.8M | $528.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $99.7M | $103.2M | $114.1M | $116.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $620.3M | $624.6M | $529.6M | $452.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $720.0M | $727.8M | $643.7M | $568.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $83.1M | $79.8M | $65.0M | -$17.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $54.1M | $51.0M | $36.1M | -$40.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $133K | $137K | $22K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $69.4M | $65.7M | $58.5M | -$19.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$65.7M | -$79.7M | $4.9M | $1.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $135.0M | $145.4M | $53.5M | -$21.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $4.66 | $4.95 | $1.80 | $-0.72 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 28.84M | 29.37M | 29.76M | 29.30M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 28.94M | 29.76M | 30.54M | 29.30M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$200.6M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.01
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-12.0%
Cash Change
+19.5%
Margin Change
+1.8 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included cash levels, debt levels, net income margin. Pressure indicators included revenue growth, EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 7.6%. EPS declined 109.0%. Cash increased 19.5%. Total debt declined 12.0%. Net income margin improved by 1.8 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Inspire Medical Systems Inc (INSP) Stock Up 3.3% and Still Undervalued -- GF Score: 64/100
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Is It Too Late to Buy Inspire Medical Systems Inc (INSP) After 5.5% Rally? GF Value Says Undervalued
Hsbc Holdings PLC Has $274,000 Stock Holdings in Inspire Medical Systems, Inc. $INSP
Rumor Mill · INSP
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial